Article
Multidisciplinary Sciences
Fan-Yu Chen, Chun-Fan Chen, Ann Charis Tan, Chia-Hao Chan, Fu-An Chen, Wen-Sheng Liu, Tz-Heng Chen, Shuo-Ming Ou, Szu-Yuan Li, Ming-Tsun Tsai, Yung-Tai Chen, Chih-Ching Lin
Summary: Patients with systemic lupus erythematosus (SLE) have a higher incidence of arteriovenous fistula or graft (AVF/AVG) dysfunction during long-term follow-up, necessitating regular monitoring to improve vascular access function.
SCIENTIFIC REPORTS
(2021)
Article
Rheumatology
Amaia Ugarte, Alazne Garcia de Bustos, Ioana Ruiz-Arruza, Adriana Soto-Peleteiro, Daniel Martin-Iglesias, Cristina Gonzalez-Echavarri, Guillermo Ruiz-Irastorza
Summary: This study compared the influence of aPLs on global and cardiovascular damage in patients with SLE diagnosed before and after the year 2000. The results showed that the effects of aPL on damage accrual in SLE patients have been reduced over recent years, possibly due to the widespread use of HCQ and improved thromboprophylaxis.
Article
Medicine, Research & Experimental
Elena Gkrouzman, Rohan Willis, Danieli Andrade, Maria G. Tektonidou, Vittorio Pengo, Guillermo Ruiz-Irastorza, H. Michael Belmont, Paul R. Fortin, Maria Gerosa, Flavio Signorelli, Tatsuya Atsumi, D. Ware Branch, Cecilia Nalli, Esther Rodriguez-Almaraz, Michelle A. Petri, Ricard Cervera, Jason S. Knight, Maria Efthymiou, Hannah Cohen, Maria Laura Bertolaccini, Doruk Erkan, Robert Roubey
Summary: A study found that different profiles of antiphospholipid antibody (aPL) are associated with the clinical manifestations of antiphospholipid syndrome (APS), particularly higher levels of anticardiolipin antibody (aCL) and anti -b2 glycoprotein-I antibody (ab2GPI). The study also identified overlapping antibody detection methods and proposed a calculation method to assess the overall burden of aPL.
LABORATORY INVESTIGATION
(2023)
Article
Immunology
Michael A. Cole, Gloria F. Gerber, Shruti Chaturvedi
Summary: Complement is a major driver of antiphospholipid syndrome (APS) and a promising therapeutic target. Reliable, rapid-turnaround biomarkers are needed in APS to predict adverse clinical outcomes and determine who will benefit most from complement inhibition. Current studies highlight the inconsistencies in testing, suggesting that cell-based testing or multiplex panels may be most clinically relevant.
CLINICAL IMMUNOLOGY
(2023)
Article
Rheumatology
Selcan Demir, Jessica Li, Laurence S. Magder, Michelle Petri
Summary: The study showed that LA remained the best predictor of thrombosis in SLE patients, and adding additional aPL did not increase the risk except for anti-beta(2)-glycoprotein I IgA.
Article
Rheumatology
Luca Moroni, Paolo Righini, Giuseppe A. Ramirez, Nicola Farina, Gaia Mancuso, Enrica Bozzolo, Ignasi Rodriguez-Pinto, Ricard Cervera, Giovanni Nano, Lorenzo Dagna
Summary: This case report described aortic occlusion as a debut manifestation of catastrophic antiphospholipid syndrome (CAPS) and discussed its clinical features with a review of the literature to identify risk factors and clues for clinical practice.
Article
Hematology
Arne Vandevelde, Walid Chayoua, Bas de Laat, Gary W. Moore, Jacek Musial, Stephane Zuily, Denis Wahl, Katrien M. J. Devreese
Summary: The presence of antiphosphatidylserine/prothrombin antibodies (aPS/PT), especially with high antibody titer, is associated with the diagnosis of thrombotic antiphospholipid syndrome (TAPS).
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Rheumatology
Elena Gkrouzman, Ecem Sevim, Jackie Finik, Danieli Andrade, Vittorio Pengo, Savino Sciascia, Maria G. Tektonidou, Amaia Ugarte, Cecilia B. Chighizola, H. Michael Belmont, Chary Lopez-Pedrera, Lanlan Ji, Paul Fortin, Maria Efthymiou, Guilherme Ramires de Jesus, D. Ware Branch, Cecilia Nalli, Michelle Petri, Esther Rodriguez, Ricard Cervera, Jason S. Knight, Tatsuya Atsumi, Rohan Willis, Maria Laura Bertolaccini, Hannah Cohen, Jacob Rand, Doruk Erkan
Summary: The study revealed that approximately 80% of patients with persistently antiphospholipid antibody (aPL) positive remained stable in their aPL profiles over a 5-year follow-up period. Additionally, the decrease in triple aPL positivity at baseline was associated with increased odds of stable aPL profile.
JOURNAL OF RHEUMATOLOGY
(2021)
Review
Medicine, Research & Experimental
Claudia Mihaela Gavris, Laurentiu Danut Nedelcu, Alina Mihaela Pascu
Summary: Antiphospholipid syndrome (APS) is recognized as a systemic autoimmune disease and a major acquired thrombophilia that affects various vascular territories, with unpredictable evolution in terms of thrombotic events. Proper stratification of thrombotic risk in patients with APS should include classic biological markers, phenotype assessment, and genetic determinants. New non-conventional serological markers, along with genetic risk factors for thrombosis, are gaining importance in thrombotic risk evaluation in APS patients.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Rheumatology
L. Riancho-Zarrabeitia, V. Martinez-Taboada, I. Rua-Figueroa, F. Alonso, M. Galindo-Izquierdo, J. Ovalles, A. Olive-Marques, N. Mena Vazquez, J. Calvo-Alen, R. Menor-Almagro, E. Tomero-Muriel, E. Uriarte-Isacelaya, A. Botenau, M. Andres, M. Freire-Gonzalez, G. Santos Soler, E. Ruiz-Lucea, M. Ibanez-Barcelo, I. Castellvi, C. Galisteo, V. Quevedo Vila, E. Raya, J. Narvaez, L. Exposito, J. A. Hernandez-Beriain, L. Horcada, E. Aurrecoechea, J. M. Pego-Reigosa
Summary: The study found varying associations between different types of antiphospholipid antibodies and manifestations of SLE and APS. For example, the IgG isotypes were associated with a higher risk of more severe SLE manifestations. Moreover, the risk of neuropsychiatric and ophthalmological symptoms significantly increased with a higher number of positive aPL.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Medicine, General & Internal
Santiago Alvarez-Lopez, Maria Fernanda Ariza-Gomez, Vanessa Lopez-Montoya, John Ubeimar Catano-Bedoya, Diana Giraldo-Mendez, Fabian Jaimes
Summary: This study aimed to characterize patients with antiphospholipid syndrome (APS) and evaluate their clinical manifestations and serological findings. The results showed that most patients were female and had venous thrombotic events. Primary APS was common, and Lupus coagulation inhibitor positivity was prevalent.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2023)
Article
Hematology
Dongmei Yin, Philip G. de Groot, Marisa Ninivaggi, Katrien M. J. Devreese, Bas de Laat
Summary: Isolated lupus anticoagulant (LAC) positivity was highly associated with vascular thrombosis, even better than triple-positive samples. The levels of anti-phosphatidylserine/prothrombin antibodies (anti-PS/PT) were significantly lower in samples with isolated LAC positivity, and isolated LAC showed weaker LAC activity compared with triple-positive patients.
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Rheumatology
Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, Florian Manneville, Mary-Carmen Amigo, Zahir Amoura, Danieli Andrade, Laura Andreoli, Bahar Artim-Esen, Tatsuya Atsumi, Tadej Avcin, Michael H. Belmont, Maria Laura Bertolaccini, D. Ware Branch, Graziela Carvalheiras, Alessandro Casini, Ricard Cervera, Hannah Cohen, Nathalie Costedoat-Chalumeau, Mark Crowther, Guilherme de Jesus, Aurelien Delluc, Sheetal Desai, Maria De Sancho, Katrien M. Devreese, Reyhan Diz-Kucukkaya, Ali Duarte-Garcia, Camille Frances, David Garcia, Jean-Christophe Gris, Natasha Jordan, Rebecca K. Leaf, Nina Kello, Jason S. Knight, Carl Laskin, Alfred I. Lee, Kimberly Legault, Steve R. Levine, Roger A. Levy, Maarten Limper, Michael D. Lockshin, Karoline Mayer-Pickel, Jack Musial, Pier Luigi Meroni, Giovanni Orsolini, Thomas L. Ortel, Vittorio Pengo, Michelle Petri, Guillermo Pons-Estel, Jose A. Gomez-Puerta, Quentin Raimboug, Robert Roubey, Giovanni Sanna, Surya V. Seshan, Savino Sciascia, Maria G. Tektonidou, Angela Tincani, Denis Wahl, Rohan Willis, Cecile Yelnik, Catherine Zuily, Francis Guillemin, Karen Costenbader, Doruk Erkan
Summary: This study developed new APS classification criteria with high specificity, including clinical and laboratory domains, and improved classification accuracy through weighting and stratification.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Medicine, General & Internal
Angelo Claudio Molinari, Tiziano Martini, Laura Banov, Antonella Ierardi, Marzia Leotta, Alessandra Strangio, Rita Carlotta Santoro
Summary: Diagnosis of antiphospholipid syndrome requires clinical criteria and the presence of antiphospholipid antibodies. Lupus anticoagulant is one of the laboratory parameters used to define this condition. Currently, there are various methods available for detecting antiphospholipid antibodies, but detecting lupus anticoagulant is more challenging.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Katja Perdan-Pirkmajer, Polona Zigon, Anja Boc, Eva Podovsovnik, Sasa Cucnik, Alenka Mavri, Ziga Rotar, Ales Ambrozic
Summary: This study suggests that negative aCL and/or anti-beta 2GPI at the time of acute DVT may not require further aPL testing, while LA should be checked after discontinuation of anticoagulant therapy. Positive aCL and/or anti-beta 2GPI at the time of acute DVT have a strong positive predictive value for APS and may impact therapeutic decisions.